000			nab a22 7a 4500
999			_c16679 _d16679
003			PC16679
005			20211201111229.0
008			211201b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9876 _aAguado García, José María _eEnfermedades Infecciosas
100			_91210 _aGarcía Reyne, Ana _eMedicina Interna
245	0	0	_aTuberculosis in solid-organ transplant recipients: disease characteristics and outcomes in the current era. _h[artículo]
260			_bProgress in transplantation (Aliso Viejo, Calif.), _c2014
300			_a24(1):37-43.
500			_aFormato Vancouver: Sun HY, Muñoz P, Torre Cisneros J, Aguado JM, Lattes R, Montejo M et al. Tuberculosis in solid-organ transplant recipients: disease characteristics and outcomes in the current era. Prog Transplant. 2014 Mar;24(1):37-43.
501			_aPMID: 24598564
504			_aContiene 14 referencias
520			_aWe determined the characteristics of posttransplant tuberculosis and the impact of rifampin-based antituberculosis regimens on outcomes in the current era. Patients comprised 64 transplant recipients with tuberculosis, divided into 2 consecutive cohorts: an earlier cohort (cases occurring from 2003 to 2007) and a later cohort (cases from 2008 to 2011). Patients from the later versus earlier era had tuberculosis develop later after transplant (odds ratio, 1.01; 95% CI, 1.00-1.02; P= .05), were more likely to be liver transplant recipients (odds ratio, 4.52; 95% CI, 1.32-15.53; P= .02), and were more likely to receive tacrolimus-based immunosuppression (odds ratio, 3.24; 95% CI, 1.14-9.19; P= .03). Mortality rate was 10% in the later cohort and 21% in the earlier cohort (P= .20). Rifampin-based treatment was less likely to be used in patients with prior rejection (P= .04). However, neither rejection rate (P= .71) nor mortality (P= .93) after tuberculosis differed between recipients who received rifampin and recipients who did not. Thus, notable changes have occurred in the epidemiological characteristics of tuberculosis in transplant recipients. Overall mortality rate has improved, with about 90% of the patients now surviving after tuberculosis.
710			_96 _aServicio de Medicina Interna
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16679.pdf _ySolicitar documento
942			_2ddc _cART _n0